与不可生物降解渗透控制植入物相关的关键变量。
Critical variables associated with nonbiodegradable osmotically controlled implants.
机构信息
DURECT Corporation, 2 Results Way, Cupertino, California 95014, USA.
出版信息
AAPS J. 2010 Sep;12(3):437-42. doi: 10.1208/s12248-010-9199-8. Epub 2010 May 19.
Abstract
Osmotically controlled implants yield precise zero-order drug delivery kinetics and are utilized in a number of applications. The implants deliver drugs for extended periods (weeks to years) and exhibit good in vivo/in vitro correlation. This paper reviews critical variables associated with these implants, with a focus on release rate testing. The extended-duration kinetics can be problematic when attempting to test for >70% cumulative delivery. An innovative scheme based on the scientific principles of operation of the system is described to ensure > 70% delivery at the target rate and duration for the DUROS Viadur (leuprolide acetate) implant.
摘要
渗透控制型植入物可实现精确的零级药物释放动力学，被广泛应用于多个领域。这些植入物能够持续释放药物（数周到数年），并且具有良好的体内/体外相关性。本文主要针对药物释放率测试，回顾了与这些植入物相关的关键变量。在尝试测试超过 70%的累积释放量时，这种长时间的动力学可能会产生问题。本文描述了一种基于该系统工作原理的创新性方案，以确保在目标速率和持续时间内，DUROS Viadur（醋酸亮丙瑞林）植入物的累积释放量超过 70%。
相似文献
1
Critical variables associated with nonbiodegradable osmotically controlled implants.与不可生物降解渗透控制植入物相关的关键变量。
AAPS J. 2010 Sep;12(3):437-42. doi: 10.1208/s12248-010-9199-8. Epub 2010 May 19.
2
Chronic (60-week) toxicity study of DUROS leuprolide implants in dogs.DUROS亮丙瑞林植入剂对犬的慢性（60周）毒性研究。
Int J Toxicol. 2001 Nov-Dec;20(6):369-81. doi: 10.1080/109158101753333659.
3
An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer.
J Control Release. 2001 Jul 10;75(1-2):1-10. doi: 10.1016/s0168-3659(01)00358-3.
4
Leuprorelin implant (ALZA). DUROS, leuprolide acetate implant, leuprolide implant, Viadur.
Drugs R D. 1999 Dec;2(6):425-6. doi: 10.2165/00126839-199902060-00016.
5
Managing advanced prostate cancer with Viadur (leuprolide acetate implant).
Urol Nurs. 2001 Dec;21(6):385-8, 393-4; quiz 395-6.
6
DUROS technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months.DUROS技术能够持续以恒定速率递送肽和蛋白质，持续时间为3至12个月。
J Diabetes Sci Technol. 2008 May;2(3):461-7. doi: 10.1177/193229680800200316.
7
Controlled drug release from implantable matrices based on hydrophobic polymers.
Biomaterials. 1992;13(12):850-6. doi: 10.1016/0142-9612(92)90178-q.
8
Initial Leuprolide Acetate Release from Poly(d,l-lactide--glycolide) Forming Implants as Studied by Ultraviolet-Visible Imaging.紫外可见成像研究聚（D，L-丙交酯-乙交酯）成型植入物中醋酸亮丙瑞林的初始释放。
Mol Pharm. 2020 Dec 7;17(12):4522-4532. doi: 10.1021/acs.molpharmaceut.0c00625. Epub 2020 Nov 9.
9
Pharmacokinetics of 7 alpha-methyl-19-nortestosterone (MENT) delivery using subdermal implants in healthy men.健康男性使用皮下植入物递送7α-甲基-19-去甲睾酮（MENT）的药代动力学
Contraception. 1999 Nov;60(5):299-303. doi: 10.1016/s0010-7824(99)00095-5.
10
Kinetics and mechanism of release from glyceryl monostearate-based implants: evaluation of release in a gel simulating in vivo implantation.基于单硬脂酸甘油酯的植入剂的释放动力学与机制：在模拟体内植入的凝胶中的释放评估
J Pharm Sci. 1998 Jun;87(6):738-44. doi: 10.1021/js9703986.
引用本文的文献
1
Comprehensive Therapeutic Approaches to Tuberculous Meningitis: Pharmacokinetics, Combined Dosing, and Advanced Intrathecal Therapies.结核性脑膜炎的综合治疗方法：药代动力学、联合给药及鞘内高级治疗
Pharmaceutics. 2024 Apr 14;16(4):540. doi: 10.3390/pharmaceutics16040540.
2
Exploring the vast potentials and probable limitations of novel and nanostructured implantable drug delivery systems for cancer treatment.探索新型纳米结构可植入药物递送系统在癌症治疗中的巨大潜力和可能存在的局限性。
EXCLI J. 2024 Feb 1;23:143-179. doi: 10.17179/excli2023-6747. eCollection 2024.
3
In vivo degradation forms, anti-degradation strategies, and clinical applications of therapeutic peptides in non-infectious chronic diseases.治疗性肽在非传染性慢性疾病中的体内降解形式、抗降解策略和临床应用。
Eur J Pharmacol. 2022 Oct 15;932:175192. doi: 10.1016/j.ejphar.2022.175192. Epub 2022 Aug 16.
4
Implantable Drug Delivery Systems and Foreign Body Reaction: Traversing the Current Clinical Landscape.可植入药物递送系统与异物反应：审视当前临床现状
Bioengineering (Basel). 2021 Dec 9;8(12):205. doi: 10.3390/bioengineering8120205.
5
Elastic Bioresorbable Polymeric Capsules for Osmosis-Driven Delayed Burst Delivery of Vaccines.用于疫苗渗透驱动延迟爆发式递送的弹性可生物吸收聚合物胶囊。
Pharmaceutics. 2021 Mar 23;13(3):434. doi: 10.3390/pharmaceutics13030434.
6
Trabecular and cortical bone are unaltered in response to chronic lipopolysaccharide exposure via osmotic pumps in male and female CD-1 mice.雄性和雌性 CD-1 小鼠通过渗透泵持续暴露于脂多糖时，其小梁骨和皮质骨均无改变。
PLoS One. 2021 Feb 5;16(2):e0243933. doi: 10.1371/journal.pone.0243933. eCollection 2021.
7
Future of sustained protein delivery.持续蛋白质递送的未来。
Ther Deliv. 2014 Nov;5(11):1171-4. doi: 10.4155/tde.14.86.
8
Long-term delivery of protein therapeutics.蛋白质治疗药物的长期递送。
Expert Opin Drug Deliv. 2015 Mar;12(3):415-40. doi: 10.1517/17425247.2015.961420. Epub 2014 Sep 24.
9
Accelerated in-vitro release testing methods for extended-release parenteral dosage forms.加速释放体外测试方法用于延长释放型肠外剂型。
J Pharm Pharmacol. 2012 Jul;64(7):986-96. doi: 10.1111/j.2042-7158.2012.01482.x. Epub 2012 Mar 8.
本文引用的文献
1
Chronic (60-week) toxicity study of DUROS leuprolide implants in dogs.DUROS亮丙瑞林植入剂对犬的慢性（60周）毒性研究。
Int J Toxicol. 2001 Nov-Dec;20(6):369-81. doi: 10.1080/109158101753333659.
2
An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer.
J Control Release. 2001 Jul 10;75(1-2):1-10. doi: 10.1016/s0168-3659(01)00358-3.
3
Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer.
J Urol. 2000 Sep;164(3 Pt 1):730-4. doi: 10.1097/00005392-200009010-00026.
4
Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer.
Urology. 2000 May;55(5):639-42. doi: 10.1016/s0090-4295(00)00479-9.
5
Principles of the design and operation of generic osmotic pumps for the delivery of semisolid or liquid drug formulations.用于递送半固体或液体药物制剂的通用渗透泵的设计与操作原理。
Ann Biomed Eng. 1976 Dec;4(4):343-53. doi: 10.1007/BF02584524.
Zotero 插件